Back to top
more

VIVUS, Inc. (VVUS)

(Delayed Data from NSDQ)

$3.73 USD

3.73
58,550

+0.03 (0.81%)

Updated May 3, 2019 04:13 PM ET

After-Market: $3.83 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Valeant (VRX) Decides to Extend Stay on Xifaxan's ANDA

by Zacks Equity Research

Valeant Pharmaceuticals International, Inc. (VRX) announced that it has decided to stay outstanding litigation and extend the 30-month stay regarding Teva's ANDA for a generic version of Xifaxan 550 mg tablets.

    Incyte (INCY) Announces Positive Data on Enzyme Inhibitor

    by Zacks Equity Research

    Incyte Corporation (INCY) recently announced that new data was published from the ongoing trial, ECHO-202 online by the American Society of Clinical Oncology (ASCO).

      J&J (JNJ) Plans to Seek Approval for 10 New Drugs by 2021

      by Zacks Equity Research

      Johnson & Johnson, Inc. (JNJ) discussed its future plans and showcased a strong pipeline of transformational medicines at a meeting held yesterday with industry analysts.

        Concert Pharma Falls After Clinical Hold on Hair Loss Drug

        by Zacks Equity Research

        Concert Pharmaceuticals, Inc. (CNCE) shares were down almost 8% on Wednesday after the company announced that the FDA has placed a clinical hold on a mid-stage study evaluating its pipeline candidate CTP-543 for the treatment of alopecia areata.

          Vertex Ups Kalydeco Sales View as FDA Okays Label Expansion

          by Zacks Equity Research

          Vertex Pharmaceuticals Incorporated???s (VRTX) announced that the FDA has approved its lead marketed drug, Kalydeco (ivacaftor) for expanded use.

            Sangamo's (SGMO) Hemophilia A Drug Gets Fast-Track Status

            by Zacks Equity Research

            Sangamo Therapeutics, Inc. (SGMO) announced that the FDA has granted fast track designation to pipeline candidate, SB-525.

              Alexion's (ALXN) Strensiq Results Positive in Long-Term Study

              by Zacks Equity Research

              Alexion Pharmaceuticals, Inc. (ALXN) announced that researchers presented encouraging data on Strensiq at the European Calcified Tissue Society (ECTS) Congress in Austria.

                Kamada (KMDA) Posts Q1 Loss Wider than Expected, Sales Miss

                by Zacks Equity Research

                Kamada Ltd. (KMDA) reported adjusted loss of 11 cents in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of 3 cents.

                  Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth

                  by Zacks Equity Research

                  On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.

                    Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss

                    by Zacks Equity Research

                    Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.

                      Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now

                      by Zacks Equity Research

                      On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI).

                        Celgene's (CELG) Revlimid Looks Solid on Label Expansion

                        by Zacks Equity Research

                        Celgene's key growth driver, Revlimid, continues to outperform on the back of market share gains and increased duration.

                          Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review

                          by Zacks Equity Research

                          Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa

                            Minerva (NERV) Provides Phase III Development Strategy for MIN-101

                            by Zacks Equity Research

                            Minerva Neurosciences, Inc. (NERV) announced plans for its phase III and phase IV clinical development of pipeline candidate MIN-101.

                              Ionis (IONS) Stock Falls Despite Positive Inotersen Data

                              by Zacks Equity Research

                              Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints.

                                Why Is Vertex Pharma (VRTX) Stock Soaring This Year?

                                by Zacks Equity Research

                                Vertex Pharmaceuticals, Inc.'s (VRTX) shares have risen 57.8% this year so far, outperforming the increase of 1.3% for the Zacks classified Large-Cap Pharma industry.

                                  BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains

                                  by Zacks Equity Research

                                  BioDelivery Sciences International, Inc. (BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents.

                                    Dr. Reddy's (RDY) Earnings & Revenues Decline Y/Y in Q4

                                    by Zacks Equity Research

                                    Dr. Reddy's Laboratories Ltd. (RDY) reported fourth-quarter fiscal 2017 earnings per American Depositary Share (ADS) of 29 cents, down from 7 cents in the year-ago quarter.

                                      AbbVie and J&J Present Positive Imbruvica Leukemia Data

                                      by Zacks Equity Research

                                      AbbVie Inc. (ABBV) recently announced positive data from a pooled analysis of three phase III studies evaluating its cancer drug, Imbruvica (ibrutinib).

                                        Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1

                                        by Zacks Equity Research

                                        Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.

                                          Inovio (INO) Q1 Loss Narrower Than Expected, Revenues Beat

                                          by Zacks Equity Research

                                          Inovio Pharmaceuticals, Inc. (INO) reported loss of 31 cents for the first quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 34 cents.

                                            Jazz Pharmaceuticals (JAZZ) Misses Q1 Earnings & Sales

                                            by Zacks Equity Research

                                            Jazz Pharmaceuticals Public Limited Company (JAZZ) reported first-quarter 2017 earnings of $1.41 per share, which narrowly missed the Zacks Consensus Estimate of $1.42.

                                              Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss

                                              by Zacks Equity Research

                                              Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.

                                                Mallinckrodt Earnings, Revenues Beat Estimates in Q1

                                                by Zacks Equity Research

                                                Mallinckrodt Public Limited Company (MNK) reported first-quarter 2017 results wherein both sales and earnings beat expectations.

                                                  ImmunoGen (IMGN) Posts Narrower-than-Expected Loss in Q1

                                                  by Zacks Equity Research

                                                  ImmunoGen, Inc. (IMGN) reported a loss of 20 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of 36 cents and the year-ago loss of 37 cents.